Healthcare Jul 06, 2021 09:02 AM (GMT+8) · EqualOcean
Recently, Shanghai Shende Medical Device Technology Co., Ltd. (hereinafter referred to as "Shende medical") has completed round B and round B + financing in five months, accumulating more than 100 million yuan, EUROHEALTH said on the 6th. The two rounds of financing are jointly invested by chuangrei investment, Dianshi chuangjian, Yingfeng Dingtai, zhilang venture capital, Jianmu investment, rending investment and other funds. This round of financing is mainly used for clinical trials and marketing promotion of series products of non-invasive treatment for pain relief of hysteromyoma / adenomyosis, breast tumor and bone tumor, as well as the development and layout of series products of non-invasive treatment for Parkinson's disease / idiopathic tremor / glioma, prostate tumor and thyroid tumor. Founded in May 2013, Shende medical focuses on the R & D and production of domestic high-end precision non-invasive treatment equipment with completely independent intellectual property rights, which is used for non-invasive treatment of major diseases such as tumor and nervous system, covering the whole industrial chain of high-end medical device industrial manufacturing, commercial operation and after-sales service. Shende medical's main products come from the technical breakthrough and product operation of Mr guided phased high-intensity focused ultrasound precise non-invasive treatment system, a major scientific and technological achievement of academician Chen Yazhu's team of Shanghai Jiaotong University in 24 years. At present, Shende medical "advanced metastatic bone tumor pain relief treatment system" has completed the EU CE certification. The product and its products for other indications are in various stages of preclinical technology development and clinical in China.

This text is a result of machine translation.